WASHINGTON (Reuters) – The U.S. Senate health panel said on Tuesday it would vote later this month on whether to subpoena Novo Nordisk over the high U.S. prices for weight loss drugs Ozempic and Wegovy compared to those offered in other countries.
The Senate Committee on Health, Education, Labor, and Pensions, which is investigating the drugs’ costs, will weigh a subpoena for senior Novo Nordisk Inc executive Doug Langa when it meets on June 18, it said in a statement.
(Reporting by Susan Heavey, editing by David Ljunggren)